source
- Beeline's oral lupus drug afimetoran meets primary endpoint in Phase 2, paving way for Phase 3Beeline Medicines announced that its oral small-molecule inhibitor afimetoran achieved the primary endpoint in a 48-week Phase 2 trial in patients with systemic lupus erythematosus (SLE). The tria…
- UK commission proposes new framework to regulate AI-driven medical toolsA UK commission released a report on Thursday outlining 44 recommendations for how artificial intelligence should be governed in the medical sector. The guidance aims to capture AI's promise, such…